Surface modification and paclitaxel drug delivery of folic acid modified polyethylene glycol functionalized hydroxyapatite nanoparticles

Venkatasubbu, G. Devanand; Ramasamy, S.; Avadhani, G. S.; Ramakrishnan, V.; Kumar, J.

doi:10.1016/j.powtec.2012.11.003

Cited by 121 publications

(53 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These characteristic peaks in raw PTX are consistent with previous studies. 39,40 The same phenomenon was apparent in the FTIR curve of the PTXCMPs. Compared to the FTIR curves of raw PTX and the CMPs, 20 the absorption peaks of the PTX-CMPs were stronger and no new peak existed in the FTIR curve of PTX-loaded CMPs, indicating that the PTX had been encapsulated in the CMPs by a physical process, without any change in the functional groups of the materials used.…”

Section: Drug Load Encapsulation Efficiency and Physicochemical Prosupporting

confidence: 56%

Preparation and antitumor effect evaluation of composite microparticles co-loaded with siRNA and paclitaxel by a supercritical process

et al. 2015

View full text Add to dashboard Cite

The co-delivery of siRNA and therapeutic agents provides an effective method for cancer chemotherapy by avoiding drug resistance during the treatment. With a combination of ionic gelation and supercritical fluid technology, nanoparticle-embedded composite microparticles (CMPs) co-loaded with siRNA and paclitaxel (siRNA-PTX-CMPs) were successfully prepared. The results show that CMPs embedded with nanoparticles with a diameter of 50-100 nm exhibited a spherical shape and core-shell structure with a 10 mean diameter of 323 nm. The encapsulation efficiency of siRNA in chitosan nanoparticles (CS NPs) was 96.97%. The drug load and encapsulation efficiency of PTX-loaded CMPs (5% dosage) were 1.40% and 27.95%, respectively; these both increased with an increase in dosage. It was found that no change had occurred in the functional groups of the components during the supercritical process, while the physical form of PTX had shifted to an amorphous state. In the cell experiments, the CMPs clustered around the 15 nucleus after being uptaken by the Bcap-37 cells. The results of the antitumor effect experiments revealed that the co-loaded siRNA-PTX-CMPs achieved a significantly better synergistic effect than single dosages, which indicated that the co-delivery system developed by the supercritical process could have potential in the application of cancer chemotherapy.

show abstract

Section: Drug Load Encapsulation Efficiency and Physicochemical Prosupporting

confidence: 56%

Preparation and antitumor effect evaluation of composite microparticles co-loaded with siRNA and paclitaxel by a supercritical process

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The studies performed by Venkatasubbu et al confirmed the effectiveness of PEG functionalized HAp nanoparticles as a drug carrier . Anticancer drug paclitaxel could be effectively attached to the surface of folic acid modified PEG‐functionalized HAp surface.…”

Section: Hydroxyapatite As a Drug Carriermentioning

confidence: 99%

Recent progress on fabrication and drug delivery applications of nanostructured hydroxyapatite

Mondal

Dorozhkin

Pal

2017

WIREs Nanomed Nanobiotechnol

154

104

View full text Add to dashboard Cite

Through this brief review, we provide a comprehensive historical background of the development of nanostructured hydroxyapatite (nHAp), and its application potentials for controlled drug delivery, drug conjugation, and other biomedical treatments. Aspects associated with efficient utilization of hydroxyapatite (HAp) nanostructures such as their synthesis, interaction with drug molecules, and other concerns, which need to be resolved before they could be used as a potential drug carrier in body system, are discussed. This review focuses on the evolution of perceptions, practices, and accomplishments in providing improved delivery systems for drugs until date. The pioneering developments that have presaged today's fascinating state of the art drug delivery systems based on HAp and HAp-based composite nanostructures are also discussed. Special emphasis has been given to describe the application and effectiveness of modified HAp as drug carrier agent for different diseases such as bone-related disorders, carriers for antibiotics, anti-inflammatory, carcinogenic drugs, medical imaging, and protein delivery agents. As only a very few published works made comprehensive evaluation of HAp nanostructures for drug delivery applications, we try to cover the three major areas: concepts, practices and achievements, and applications, which have been consolidated and patented for their practical usage. The review covers a broad spectrum of nHAp and HAp modified inorganic drug carriers, emphasizing some of their specific aspects those needed to be considered for future drug delivery applications. This article is categorized under: Implantable Materials and Surgical Technologies > Nanomaterials and Implants Therapeutic Approaches and Drug Discovery > Nanomedicine for Respiratory Disease Nanotechnology Approaches to Biology > Cells at the Nanoscale.

show abstract

“…The excipient enhances the adhesion of the drug to the balloon surface, increases the stability of the drug coating during handling and delivery, and maximizes drug retention to the targeted arterial segment. [18][19][20][21][22][23][24] Current DCBs excipients include polysorbate and sorbitol, urea, polyethylene glycol (PEG) and butyryl-tri-hexyl citrate (BTHC). The rationale for the selection of these various excipients varies.…”

Section: Introductionmentioning

confidence: 99%

Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons

et al. 2020

View full text Add to dashboard Cite

Background: Drug-coated balloons (DCBs), which deliver anti-proliferative drugs with the aid of excipients, have emerged as a new endovascular therapy for the treatment of peripheral arterial disease. In this study, we evaluated the use of keratose (KOS) as a novel DCB-coating excipient to deliver and retain paclitaxel. Methods: A custom coating method was developed to deposit KOS and paclitaxel on uncoated angioplasty balloons. The retention of the KOS-paclitaxel coating, in comparison to a commercially available DCB, was evaluated using a novel vascular-motion simulating ex vivo flow model at 1 h and 3 days. Additionally, the locoregional biological response of the KOS-paclitaxel coating was evaluated in a rabbit ilio-femoral injury model at 14 days. Results: The KOS coating exhibited greater retention of the paclitaxel at 3 days under pulsatile conditions with vascular motion as compared to the commercially available DCB (14.89 ± 4.12 ng/mg vs. 0.60 ± 0.26 ng/mg, p = 0.018). Histological analysis of the KOS–paclitaxel-treated arteries demonstrated a significant reduction in neointimal thickness as compared to the uncoated balloons, KOS-only balloon and paclitaxel-only balloon. Conclusions: The ability to enhance drug delivery and retention in targeted arterial segments can ultimately improve clinical peripheral endovascular outcomes.

show abstract

Surface modification and paclitaxel drug delivery of folic acid modified polyethylene glycol functionalized hydroxyapatite nanoparticles

Cited by 121 publications

References 27 publications

Preparation and antitumor effect evaluation of composite microparticles co-loaded with siRNA and paclitaxel by a supercritical process

Preparation and antitumor effect evaluation of composite microparticles co-loaded with siRNA and paclitaxel by a supercritical process

Recent progress on fabrication and drug delivery applications of nanostructured hydroxyapatite

Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons

Contact Info

Product

Resources

About